118 related articles for article (PubMed ID: 2669756)
1. Structure and activity of the B-chain of insulin.
Ng FM; Zhu SQ; Cui DF; Fan L; Huang YD; Zhang YS
Biochem Int; 1989 Feb; 18(2):373-81. PubMed ID: 2669756
[TBL] [Abstract][Full Text] [Related]
2. Effects of a synthetic hexapeptide (beta-Ala-Arg-Gly-Phe-Phe-Tyr-Nh2) on insulin binding and glucose metabolism of rat adipocytes.
Taketomi S; Iwatsuka H
Horm Metab Res; 1979 Oct; 11(9):498-502. PubMed ID: 500000
[No Abstract] [Full Text] [Related]
3. Shortened insulin analogues: marked changes in biological activity resulting from replacement of TyrB26 and N-methylation of peptide bonds in the C-terminus of the B-chain.
Záková L; Barth T; Jirácek J; Barthová J; Zórad S
Biochemistry; 2004 Mar; 43(8):2323-31. PubMed ID: 14979729
[TBL] [Abstract][Full Text] [Related]
4. [Insulin receptors-a review (author's transl)].
Freychet P
Diabete Metab; 1975 Mar; 1():57-68. PubMed ID: 791721
[TBL] [Abstract][Full Text] [Related]
5. Effects of hexapeptide, a compound analogous to insulin B chain fragment B-21-26(DP-432) on the glucose uptake into the perfused hind limb of rats.
Toyota T; Kitahara A; Goto Y
Horm Metab Res; 1978 Jan; 10(1):17-20. PubMed ID: 631735
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like activities and insulin-potentiating actions of a modified insulin B21-26 fragment: beta-Ala-Arg-Gly-Phe-Phe-Tyr-NH2.
Fujino M; Wakimasu M; Taketomi S; Iwatsuka H
Endocrinology; 1977 Aug; 101(2):360-4. PubMed ID: 885107
[TBL] [Abstract][Full Text] [Related]
7. Insulin analogues with modifications at position B26. Divergence of binding affinity and biological activity.
Záková L; Kazdová L; Hanclová I; Protivínská E; Sanda M; Budesínský M; Jirácek J
Biochemistry; 2008 May; 47(21):5858-68. PubMed ID: 18452310
[TBL] [Abstract][Full Text] [Related]
8. Nonsuppressible insulin-like activity: biological activity and receptor binding.
Zapf J; Mäder M; Waldvogel M; Froesch ER
Isr J Med Sci; 1975 Jul; 11(7):664-78. PubMed ID: 169212
[No Abstract] [Full Text] [Related]
9. Hypoglycemic action of a novel constrained analog of human growth hormone-(6-13).
Lim N; Ng FM; Wu ZM; Ede N; Hearn MT
Endocrinology; 1992 Aug; 131(2):835-40. PubMed ID: 1639027
[TBL] [Abstract][Full Text] [Related]
10. pI-shifted insulin analogs with extended in vivo time action and favorable receptor selectivity.
Kohn WD; Micanovic R; Myers SL; Vick AM; Kahl SD; Zhang L; Strifler BA; Li S; Shang J; Beals JM; Mayer JP; DiMarchi RD
Peptides; 2007 Apr; 28(4):935-48. PubMed ID: 17328992
[TBL] [Abstract][Full Text] [Related]
11. Correlation between insulin receptor occupancy and tyrosine kinase activity at low insulin concentrations and effect of major histocompatibility complex class I-derived peptide.
Stagsted J; Hansen T; Roth RA; Goldstein A; Olsson L
J Pharmacol Exp Ther; 1993 Nov; 267(2):997-1001. PubMed ID: 8246175
[TBL] [Abstract][Full Text] [Related]
12. An examination of the role of insulin dimerisation and negative cooperativity using the biological properties of the despentapeptide and deshexapeptide insulins.
Cockram CS; Jones RH; Sonksen PH; Tatnell MA; Zhu SQ; Dodson G
Diabetologia; 1987 Sep; 30(9):733-8. PubMed ID: 3322916
[TBL] [Abstract][Full Text] [Related]
13. Direct demonstration of separate receptors for growth and metabolic activities of insulin and multiplication-stimulating activity (an insulinlike growth factor) using antibodies to the insulin receptor.
King GL; Kahn CR; Rechler MM; Nissley SP
J Clin Invest; 1980 Jul; 66(1):130-40. PubMed ID: 6995478
[TBL] [Abstract][Full Text] [Related]
14. [A synthetic fragment of insulin with insulin-like biological activity].
Prozorovskiĭ VN; Maksimova EM; Alekseeva AE; Grebenshchikova OG; Abakumova OIu; Kutsenko NG; Tsvetkova TA; Archakov AI
Vopr Med Khim; 1996; 42(4):284-91. PubMed ID: 9254511
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationship of synthetic phosphoinositolglycans mimicking metabolic insulin action.
Frick W; Bauer A; Bauer J; Wied S; Müller G
Biochemistry; 1998 Sep; 37(38):13421-36. PubMed ID: 9748349
[TBL] [Abstract][Full Text] [Related]
16. Interrelationships among receptor structures for insulin and peptide growth factors.
Czech MP; Oppenheimer CL; Massagué J
Fed Proc; 1983 Jun; 42(9):2598-601. PubMed ID: 6303863
[TBL] [Abstract][Full Text] [Related]
17. Insulin receptor function and glycogen synthase activity in human skeletal muscle. Physiology and pathophysiology.
Bak JF
Dan Med Bull; 1994 Apr; 41(2):179-92. PubMed ID: 8039433
[TBL] [Abstract][Full Text] [Related]
18. Structure and activity of insulin, XIII. Specificity of the arginine-guanidino group in biologically active tetrapeptides of the insulin sequence B 22-25 (Arg-Gly-Phe-Phe).
Weitzel G; Eisele K; Stock W
Hoppe Seylers Z Physiol Chem; 1975 May; 356(5):583-90. PubMed ID: 1158333
[TBL] [Abstract][Full Text] [Related]
19. A shortened insulin with full in vitro potency.
Fischer WH; Saunders D; Brandenburg D; Wollmer A; Zahn H
Biol Chem Hoppe Seyler; 1985 May; 366(5):521-5. PubMed ID: 3890892
[TBL] [Abstract][Full Text] [Related]
20. Biological properties of an initial degradation product of insulin by insulin-degrading enzyme.
Yonezawa K; Yokono K; Shii K; Hari J; Yaso S; Sakamoto T; Kawase Y; Akiyama H; Taketomi S; Baba S
Endocrinology; 1989 Jan; 124(1):496-504. PubMed ID: 2642422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
